52957-65-0

Basic information

• Product Name: 5,6-DIAMINOINDANE
• Synonyms: 5,6-DIAMINOINDANE
• CAS NO: 52957-65-0
• Molecular Formula: C9H12N2
• Molecular Weight: 148.2
• Mol File: 52957-65-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6-DIAMINOINDANE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DIAMINOINDANE(52957-65-0)
• EPA Substance Registry System: 5,6-DIAMINOINDANE(52957-65-0)

Safety Data

• Hazardous Substances Data: 52957-65-0(Hazardous Substances Data)

Upstream product

• 59856-06-3 5-acetamidoindane 
• 55491-36-6 5-acetamino-6-nitro-indane 
• 24425-40-9 indan-5-amine 
• 52957-66-1 5-amino-6-nitroindane 

Downstream Products

• 81864-39-3 2-mercaptocyclopentano<1,2-f>benzimidazole 
• 133100-21-7 2-amino-1,5,6,7-tetrahydroindeno<5,6-d>imidazole 

Relevant articles and documents

Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.

Receptor-based design of novel dihydrofolate reductase inhibitors: Benzimidazole and indole derivatives

Although many thousands of inhibitors of the enzyme dihydrofolate reductase (DHFR) have been synthesized, all of the very active compounds have been 2,4-diaminopyrimidines or very close analogues. This paper describes 2,4-diamino-6-benzylbenzimidazole (3b